ES2000743A6 - Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos. - Google Patents

Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.

Info

Publication number
ES2000743A6
ES2000743A6 ES8600558A ES8600558A ES2000743A6 ES 2000743 A6 ES2000743 A6 ES 2000743A6 ES 8600558 A ES8600558 A ES 8600558A ES 8600558 A ES8600558 A ES 8600558A ES 2000743 A6 ES2000743 A6 ES 2000743A6
Authority
ES
Spain
Prior art keywords
tpa
dosage unit
reconstitution
pharmaceutical dosage
sterile containers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8600558A
Other languages
English (en)
Inventor
Thomas Robert Melefyt
Chester Allen Meyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of ES2000743A6 publication Critical patent/ES2000743A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL ESTUCHE DESCRITO COMPRENDE UNO O MAS RECIPIENTES ESTERILES DE TPA (ACTIVADOR DE PLASMINOGENO DE TEJIDOS HUMANOS) EN FORMA LIOFILIZADA Y UNO O MAS RECIPIENTES ESTERILES DISTINTOS DE SOLUCION PARA RECONSTITUCION, HABIENDO UN TAMPON EN UNO O AMBOS RECIPIENTES Y SELECCIONANDOSE EL TAMPON, LA SOLUCION PARA RECONSTITUCION Y LAS CANTIDADES DE TPA Y DE SOLUCION DE MANERA QUE PROPORCIONEN UNA UNIDAD DE DOSIFICACION FARMACEUTICA QUE COMPRENDE 0,1-15 MG/ML DE TPA A PH 3,5-5,5. POR SU PARTE, EL PROCEDIMIENTO COMPRENDE DISOLVER TPA EN UN DISOLVENTE ACUOSO AL PH CITADO HASTA ALCANZAR LA CONCENTRACION DEL TPA MENCIONADA. LA UNIDAD DE DOSIFICACION OBTENIDA ES UTIL PARA ADMINISTRACION PARENTERAL, PARTICULARMENTE EN TERAPIA TROMBOLITICA.-
ES8600558A 1985-07-29 1986-07-24 Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos. Expired ES2000743A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75978585A 1985-07-29 1985-07-29

Publications (1)

Publication Number Publication Date
ES2000743A6 true ES2000743A6 (es) 1988-03-16

Family

ID=25056946

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8600558A Expired ES2000743A6 (es) 1985-07-29 1986-07-24 Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.

Country Status (15)

Country Link
EP (1) EP0211592A3 (es)
JP (1) JPS6236332A (es)
KR (1) KR870000918A (es)
CN (1) CN86105526A (es)
AU (1) AU593566B2 (es)
DK (1) DK352686A (es)
ES (1) ES2000743A6 (es)
FI (1) FI863077A7 (es)
GR (1) GR861961B (es)
HU (1) HU198264B (es)
NO (1) NO863029L (es)
PH (1) PH22989A (es)
PT (1) PT83075B (es)
ZA (1) ZA865652B (es)
ZW (1) ZW14486A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
DE3806562A1 (de) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
CA2027936C (en) 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
CA2107476C (en) * 1991-04-16 2007-12-18 Martin Ulrich Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
KR102194891B1 (ko) 2020-07-08 2020-12-28 대상 주식회사 계란프라이 조리장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
FI863077L (fi) 1987-01-30
CN86105526A (zh) 1987-02-04
DK352686A (da) 1987-01-30
PT83075B (en) 1988-07-13
EP0211592A3 (en) 1988-03-02
AU593566B2 (en) 1990-02-15
EP0211592A2 (en) 1987-02-25
DK352686D0 (da) 1986-07-24
NO863029D0 (no) 1986-07-28
JPS6236332A (ja) 1987-02-17
ZA865652B (en) 1987-11-25
KR870000918A (ko) 1987-03-10
GR861961B (en) 1986-11-26
AU6064786A (en) 1987-02-05
ZW14486A1 (en) 1986-10-22
HUT42953A (en) 1987-09-28
FI863077A7 (fi) 1987-01-30
FI863077A0 (fi) 1986-07-28
HU198264B (en) 1989-09-28
NO863029L (no) 1987-01-30
PT83075A (en) 1986-08-01
PH22989A (en) 1989-02-24

Similar Documents

Publication Publication Date Title
FI875533L (fi) Insulinpreparat foer non-parenteral dosering.
ES2060593T3 (es) Sistema de aporte de farmacos.
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
ATE163849T1 (de) Arzneimittel enthaltend als wirkstoff r-alpha- liponsäure oder s-alpha-liponsäure
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
SE8602405L (sv) Ny formulering
ES2037136T3 (es) Procedimiento para la preparacion de una solucion con elevada actividad volumetrica de una proteina con actividad de activador de plasminogeno de tejidos (t-pa).
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
Levy et al. Pharmaceutical formulation and therapeutic efficacy
DK47089A (da) Middel med oedelaeggende virkning paa maligne tumorer, fremgangsmaade til fremstilling af saadanne midler og anvendelse af disse til terapeutisk behandling af cancer
DE69008513D1 (de) Pharmazeutische formulierung von plasminogenaktivatorproteinen.
KR910005858A (ko) 지방산 요법
ES478272A1 (es) Un procedimiento para la preparacion de una solucion acuosa esteril y estable de cisplatina.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
US3725553A (en) Method for activating the blood fibrinolysis by administration of 2-amino-ethanesulphonic acid or salts thereof
Falanga et al. Topically applied recombinant tissue plasminogen activator for the treatment of venous ulcers: Preliminary report
Brush et al. The effect of the topical application of several substances on the healing of experimental cutaneous wounds
ATE56147T1 (de) T-pa enthaltende medizinische zubereitung und deren verwendung.
GB2120529A (en) Methods of preparing and using intravenous nutrient compositions
ES2062438T3 (es) Asociacion de vitamina a en dosis fisiologica y de diferentes principios activos que tienen una actividad terapeutica.
NO961046L (no) Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
AR002001A1 (es) Solucion para administracion intravenosa de lubeluzol, procedimiento para su preparacion, una jeringa previamente llenada, un paquete para infusion parael tratamiento agudo del infarto y el uso de sustancias acidas o basicas en una solucion.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000503